Market Movers

Elevance Health, Inc.’s Stock Price Skyrockets to $538.48, Achieving a Stellar 6.14% Increase

Elevance Health, Inc. (ELV)

538.48 USD +31.14 (+6.14%) Volume: 4.05M

Elevance Health, Inc.’s stock price sees a robust performance, soaring to 538.48 USD, an impressive +6.14% increase within this trading session. With a hefty trading volume of 4.05M and a year-to-date percentage change of +14.19%, ELV’s stock continues to showcase a promising upward trend, attracting savvy investors seeking substantial returns.


Latest developments on Elevance Health, Inc.

Elevance Health, Inc. (NYSE:ELV) has been making waves in the stock market recently, with its stock outperforming competitors and receiving positive recommendations from analysts. Despite some losses on a particular trading day, the company has shown resilience and strong performance. Baird recently initiated coverage of Elevance Health with an outperform recommendation, while Legacy Advisors LLC sold off some shares. Analysts at Robert W. Baird and JPMorgan Chase & Co. have also provided positive outlooks for the company, with a new price target set at $631.00 and an upgrade to a strong-buy rating by StockNews.com. Investors are keeping a close eye on Elevance Health’s stock movements as it continues to show promising growth potential.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars